Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Trans Am Clin Climatol Assoc ; 126: 20-45, 2015.
Article in English | MEDLINE | ID: mdl-26330657

ABSTRACT

The conquest of pellagra is commonly associated with one name: Joseph Goldberger of the US Public Health Service, who in 1914 went south, concluded within 4 months that the cause was inadequate diet, spent the rest of his life researching the disease, and--before his death from cancer in 1929--found that brewer's yeast could prevent and treat it at nominal cost. It does Goldberger no discredit to emphasize that between 1907 and 1914 a patchwork coalition of asylum superintendents, practicing physicians, local health officials, and others established for the first time an English-language competence in pellagra, sifted through competing hypotheses, and narrowed the choices down to two: an insect-borne infection hypothesis, championed by the flamboyant European Louis Westerna Sambon, and the new "vitamine hypothesis," proffered by Casimir Funk in early 1912 and articulated later that year by two members of the American Clinical and Climatological Association, Fleming Mant Sandwith and Rupert Blue. Those who resisted Goldberger's inconvenient truth that the root cause was southern poverty drew their arguments largely from the Thompson-McFadden Pellagra Commission, which traces back to Sambon's unfortunate influence on American researchers. Thousands died as a result.


Subject(s)
Dietary Supplements/history , Pellagra/history , Saccharomyces cerevisiae , United States Public Health Service/history , Vitamins/history , Dietary Supplements/economics , Health Care Costs , History, 20th Century , Humans , Nutritional Status , Pellagra/diagnosis , Pellagra/mortality , Pellagra/prevention & control , Pellagra/therapy , Poverty/history , Risk Factors , Treatment Outcome , United States/epidemiology , United States Public Health Service/economics , Vitamins/economics , Vitamins/therapeutic use
2.
Am Fam Physician ; 91(10): 692-7, 2015 May 15.
Article in English | MEDLINE | ID: mdl-25978198

ABSTRACT

Common questions that arise regarding treatment of gastroesophageal reflux disease (GERD) include which medications are most effective, when surgery may be indicated, which patients should be screened for Barrett esophagus and Helicobacter pylori infection, and which adverse effects occur with these medications. Proton pump inhibitors (PPIs) are the most effective medical therapy, and all PPIs provide similar relief of GERD symptoms. There is insufficient evidence to recommend testing for H. pylori in patients with GERD. In the absence of alarm symptoms, endoscopy is not necessary to make an initial diagnosis of GERD. Patients with alarm symptoms require endoscopy. Screening for Barrett esophagus is not routinely recommended, but may be considered in white men 50 years or older who have had GERD symptoms for at least five years. Symptom remission rates in patients with chronic GERD are similar in those who undergo surgery vs. medical management. PPI therapy has been associated with an increased risk of hip fracture, hypomagnesemia, community-acquired pneumonia, vitamin B12 deficiency, and Clostridium difficile infection.


Subject(s)
Gastroesophageal Reflux , Proton Pump Inhibitors , Diagnosis, Differential , Disease Management , Endoscopy/methods , Gastroesophageal Reflux/complications , Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/physiopathology , Gastroesophageal Reflux/therapy , Humans , Medication Therapy Management , Proton Pump Inhibitors/administration & dosage , Proton Pump Inhibitors/adverse effects , Secondary Prevention/methods , Symptom Assessment/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...